Innovent's Sycume approved in China for thyroid eye disease

Innovent Biologics (HKEX:1801) announced that SYCUME®, its recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, has received approval from China's National Medical Products Administration (NMPA) for the treatment of thyroid eye disease (TED). As China’s first approved IGF-1R antibody drug, SYCUME® addresses a 70-year gap in treatment options. The approval is based on Phase 3 clinical trial results showing an 85.8% proptosis reduction in patients. TED, affecting primarily women in the 40-60 age group, can cause vision impairment and blindness. SYCUME® offers a new treatment approach, addressing limitations of current glucocorticoid therapies and potentially becoming a first-line option for significant proptosis or diplopia. The company says this marks a key milestone and reinforces commitment to advancing innovation and patient care.